Magnisense designs, develops and commercializes emergency diagnostic
tests for cardiovascular diseases using its MIAtek technology and its
proprietary instrument. The MIAtek, featuring groundbreaking technology
using magnetic nanoparticles, is protected by five families of patents
issued in Europe and the United States.
Magnisense was founded by the inventor of the technology and a group of
business angels. The main investors are Daniel Bernard and Jean-Patrick
Voisin. Its head office is in Paris, and its R&D laboratory, "Le Campus", is
located in the Lyon Biopôle. Magnisense aims to become a leader in emergency
cardiac diagnosis by commercializing competitive tests that address
healthcare and economic issues.